title: Indemnity for orthoptist-delivered intravitreal injections.
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: DaCosta
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: R
authors.initials: R
authors.lastname: Hamilton
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: J
authors.initials: J
authors.lastname: Nago
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: A
authors.initials: A
authors.lastname: Mapani
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: E
authors.initials: E
authors.lastname: Kennedy
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: T
authors.initials: T
authors.lastname: Luckett
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: C
authors.initials: C
authors.lastname: Pavesio
authors.affiliation: Moorfields Eye Hospital, London, UK.
authors.forename: D
authors.initials: D
authors.lastname: Flanagan
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D006284:Health Plan Implementation / Q000458:organization & administration*; D006801:Humans; D058449:Intravitreal Injections; D009313:National Health Programs / Q000458:organization & administration*; D009722:Nurse Practitioners; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors